147 related articles for article (PubMed ID: 8957240)
21. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
22. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Langenegger D; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1999 Oct; 128(3):613-20. PubMed ID: 10516640
[TBL] [Abstract][Full Text] [Related]
23. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
[TBL] [Abstract][Full Text] [Related]
24. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain.
López-Giménez JF; Vilaró MT; Palacios JM; Mengod G
Neuropharmacology; 1998 Sep; 37(9):1147-58. PubMed ID: 9833645
[TBL] [Abstract][Full Text] [Related]
25. Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor.
Schlachter SK; Poel TJ; Lawson CF; Dinh DM; Lajiness ME; Romero AG; Rees SA; Duncan JN; Smith MW
Eur J Pharmacol; 1997 Mar; 322(2-3):283-6. PubMed ID: 9098699
[TBL] [Abstract][Full Text] [Related]
26. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.
Seeman P; Corbett R; Van Tol HH
Neuropsychopharmacology; 1997 Feb; 16(2):93-110; discussion 111-35. PubMed ID: 9015795
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a novel iodinated ligand, IPMPP, for human dopamine D4 receptors expressed in CHO cells.
Kung MP; Stevenson DA; Zhuang ZP; Vessotskie JM; Chumpradit S; Sun XM; Kung HF
Life Sci; 1997; 60(2):91-100. PubMed ID: 9000114
[TBL] [Abstract][Full Text] [Related]
28. New hexahydrocarbazoles and spiro indoles, and their affinity for D2 dopamine and 5-HT2A serotonin receptors.
Fernández F; García-Mera X; Rodríguez G; Urrutia A
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1006-9. PubMed ID: 10434402
[TBL] [Abstract][Full Text] [Related]
29. Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
Unangst PC; Capiris T; Connor DT; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
J Med Chem; 1997 Aug; 40(17):2688-93. PubMed ID: 9276014
[TBL] [Abstract][Full Text] [Related]
30. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
31. Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor.
Seeman P; Guan HC
Synapse; 2009 Oct; 63(10):935-9. PubMed ID: 19588471
[TBL] [Abstract][Full Text] [Related]
32. Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists.
Malleron JL; Comte MT; Gueremy C; Peyronel JF; Truchon A; Blanchard JC; Doble A; Piot O; Zundel JL; Huon C
J Med Chem; 1991 Aug; 34(8):2477-83. PubMed ID: 1908521
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
34. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain.
Sumiyoshi T; Ichikawa J; Meltzer HY
Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
[TBL] [Abstract][Full Text] [Related]
36. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells.
Lawson CF; Mortimore RA; Schlachter SK; Smith MW
Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):303-7. PubMed ID: 7934308
[TBL] [Abstract][Full Text] [Related]
38. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors.
Newman-Tancredi A; Audinot-Bouchez V; Gobert A; Millan MJ
Eur J Pharmacol; 1997 Jan; 319(2-3):379-83. PubMed ID: 9042615
[TBL] [Abstract][Full Text] [Related]
39. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
[TBL] [Abstract][Full Text] [Related]
40. [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors.
Gonzalez AM; Sibley DR
Eur J Pharmacol; 1995 Jan; 272(1):R1-3. PubMed ID: 7713138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
